Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 501–600 of 1,007
Molecular targeted therapy for carcinoid and islet-cell carcinoma
Yao, J. C. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.01.006 · Cited by 115
Plexiform Angiomyxoid Myofibroblastic Tumor of the Stomach
Takahashi, Y., Shimizu, S., Ishida, T., Aita, K., Toida, S., Fukusato, T., & Mori, S. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213448.54643.2f · Cited by 115
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
Druker, B. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206081 · Cited by 130
Self-citationVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Biomarkers in Pancreatic Cancer: Diagnostic, Prognostic, and Predictive
Fong, Z. V., & Winter, J. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827654ea · Cited by 116
Cesne, A. L., Glabbeke, M. M. V., Verweij, J., Casali, P. G., Findlay, M. P. N., Reichardt, P., Issels, R. D., Judson, I. R., Schöffski, P., Leyvraz, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3330 · Cited by 114
First-Line Therapy for Metastatic Soft Tissue Sarcoma
Meyer, M., & Seetharam, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0606-9 · Cited by 128
Transcriptomics and solid tumors: The next frontier in precision cancer medicine
Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 130
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 141
Nishida, T., Kanda, T., Nishitani, A., Takahashi, T., Nakajima, K., Ishikawa, T., & Hirota, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00727.x · Cited by 115
Russell, K. N., Mehler, S. J., Skorupski, K. A., Baez, J. L., Shofer, F. S., & Goldschmidt, M. H. (2007) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.230.9.1329 · Cited by 114
Gastrointestinal Stromal Tumors of the Stomach: CT Findings and Prediction of Malignancy
Kim, H., Lee, J. M., Kim, K. W., Park, S. H., Kim, S. H., Lee, J., Han, J. K., & Choi, B. I. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.183.4.1830893 · Cited by 113
Jalal, N. R., Madrakian, T., Afkhami, A., & Ghoorchian, A. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18097 · Cited by 112
STI-571: an anticancer protein-tyrosine kinase inhibitor
Roskoski, R. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.055 · Cited by 127
Screening for EGFR mutations in lung cancer, a report from India
Sahoo, R., Harini, V. V., Babu, V. C., Okaly, G. V. P., Rao, S., Nargund, A. R., Venkataswamy, E., Rao, R., & Kumar, B. S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.004 · Cited by 116
Choux, C., Carmignac, V., Bruno, C., Sagot, P., Vaiman, D., & Fauque, P. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0120-2 · Cited by 126
Eechoute, K., Fransson, M. N., Reyners, A. K. L., de Jong, F. A., Sparreboom, A., van der Graaf, W. T. A., Friberg, L. E., Schiavon, G., Wiemer, E. A. C., Verweij, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0490 · Cited by 111
Multimodality in Vivo Molecular-Genetic Imaging
Doubrovin, M., Serganova, I. S., Mayer‐Kuckuk, P., Ponomarev, V., & Blasberg, R. G. (2004) · Bioconjugate Chemistry · doi:10.1021/bc0498572 · Cited by 111
Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors
Shinomura, Y., Kinoshita, K., Tsutsui, S., & Hirota, S. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1674-0 · Cited by 111
Ambrosini, G., Cheema, H., Seelman, S. L., Teed, A. M., Sambol, E. B., Singer, S., & Schwartz, G. K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0518 · Cited by 118
Self-citationDoyle, L. A., Nelson, D., Heinrich, M. C., Corless, C. L., & Hornick, J. L. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04300.x · Cited by 117
Self-citationFukushima, S., Otsuka, A., Suzuki, T., Yanagisawa, T., Mishima, K., Mukasa, A., Saito, N., Kumabe, T., Kanamori, M., Tominaga, T., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1247-5 · Cited by 110
Loriot, Y., Perlemuter, G., Malka, D., Penault-Llorca, F. M., Boige, V., Deutsch, É., Massard, C., Armand, J. P., & Soria, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1087 · Cited by 110
Stover, E. H. (2005) · Blood · doi:10.1182/blood-2005-05-1932 · Cited by 110
Demetri, G. D., Casali, P. G., Blay, J., von Mehren, M., Morgan, J. A., Bertulli, R., Ray-Coquard, I. L., Cassier, P. A., Davey, M. P., Borghaei, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0542 · Cited by 109
Self-citationFunctional exploration of colorectal cancer genomes using Drosophila
Bangi, E., Murgia, C., Teague, A., Sansom, O. J., & Cagan, R. L. (2016) · Nature Communications · doi:10.1038/ncomms13615 · Cited by 117
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez-Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño-Garcia, A., Schalper, K. A., Segura, V., Bellmunt, J., Tabernero, J., Sweeney, C. J., Choueiri, T. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 108
Designer Therapies for Glioblastoma Multiforme
Sathornsumetee, S., & Rich, J. N. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.009 · Cited by 124
Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST
Godwin, A. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0709 · Cited by 109
Koon, H. B., Krown, S. E., Lee, J. Y., Honda, K. S., Rapisuwon, S., Wang, Z., Aboulafia, D. M., Reid, E. G., Rudek, M. A., Dezube, B. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.6365 · Cited by 111
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
Serrano, C., & George, S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1706 · Cited by 127
Li, F., Huynh, H., Li, X., Ruddy, D. A., Wang, Y., Ong, R., Chow, P., Qiu, S., Tam, A., Rakiec, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0763 · Cited by 107
Lasota, J. P., Dansonka‐Mieszkowska, A., Stachura, T., Schneider‐Stock, R., Kallajoki, M. A., Steigen, S. E., Sarlomo‐Rikala, M., Boltze, C., Kordek, R., Roessner, A., et al. (2003) · Modern Pathology · doi:10.1097/01.mp.0000097365.72526.3e · Cited by 115
NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
Podoloff, D. A., Ball, D. W., Ben‐Josef, E., Benson, A. B., Cohen, S. J., Coleman, R. E., Delbeke, D., Ho, M., Ilson, D. H., Kalemkerian, G. P., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0075 · Cited by 107
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Mócsai, A., Kovács, L., & Gergely, P. A. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-43 · Cited by 119
Diagnosis and Treatment of High-Grade Astrocytoma
Sathornsumetee, S., Rich, J. N., & Reardon, D. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.004 · Cited by 124
Schmandt, R. E., Broaddus, R. R., Lu, K. H., Shvartsman, H. S., Thornton, A., Malpica, A. L., Sun, C. C., Bodurka, D. C., & Gershenson, D. M. (2003) · Cancer · doi:10.1002/cncr.11561 · Cited by 106
Effect of Tyrosine Kinase Inhibition by Imatinib Mesylate on Mast Cell Tumors in Dogs
Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Kobayashi, T., Fujita, M., Fujino, Y., et al. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.00132.x · Cited by 105
Razis, E. D., Selviaridis, P., Labropoulos, S., Norris, J. L., Zhu, M. J., Song, D. D., Kalebic, T., Torrens, M. J., Kalogera‐Fountzila, A., Karkavelas, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1867 · Cited by 110
Self-citationPredictive in vivo animal models and translation to clinical trials
Cook, N., Jodrell, D. I., & Tuveson, D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.003 · Cited by 117
Self-citationAn update on molecular genetics of gastrointestinal stromal tumours
Tornillo, L., & Terracciano, L. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.031112 · Cited by 116
Baratti, D., Pennacchioli, E., Kusamura, S., Fiore, M., Balestra, M. R., Colombo, C., Mingrone, E., Gronchi, A., & D, M. D. M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1178-x · Cited by 105
Role of c-kit/Kit ligand signaling in regulating vasculogenesis
Heissig, B., Werb, Z., Rafii, S., & Hattori, K. (2003) · Thrombosis and Haemostasis · doi:10.1160/th03-03-0188 · Cited by 106
Alvarez-Twose, I., Matito, A., Morgado, J. M., Sánchez-Muñoz, L., Jara-Acevedo, M., García-Montero, A., Mayado, A., Caldas, C., Teodósio, C., Muñoz-González, J. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.10711 · Cited by 102
Waldherr, C., Mellinghoff, I. K., Tran, C., Halpern, B. S., Rozengurt, N., Safaei, A., Weber, W., Stout, D., Satyamurthy, N., Barrio, J. R., et al. (2005) · PubMed · Cited by 104
Cortes, J. E., Giles, F. J., O'Brien, S. M., Thomas, D. A., Albitar, M. X., Rios, M. B., Talpaz, M., Garcia‐Manero, G., Faderl, S. H., Letvak, L. A., et al. (2003) · Cancer · doi:10.1002/cncr.11416 · Cited by 109
Treatment for chronic myelogenous leukemia: the long road to imatinib
Hunter, T. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31691 · Cited by 103
Toschi, L., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0071 · Cited by 103
Proteomic Contributions to Personalized Cancer Care
Koomen, J. M., Haura, E. B., Bepler, G., Sutphen, R., Remily-Wood, E. R., Benson, K., Hussein, M., Hazlehurst, L. A., Yeatman, T. J., Hildreth, L. T., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800002-mcp200 · Cited by 103
Alterations of the c‐kit gene in testicular germ cell tumors
Sakuma, Y., Sakurai, S., Oguni, S., Hironaka, M., & Salto, K. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01470.x · Cited by 103
Imatinib treatment for gastrointestinal stromal tumour (GIST)
Lopes, L. F., & Bacchi, C. E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00983.x · Cited by 114
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Cho, J. H., Kim, K. M., Kwon, M., Kim, H. J., & Lee, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9763-9 · Cited by 108
Rolf, M. G., Curwen, J., Veldman-Jones, M. H., Eberlein, C., Wang, J., Harmer, A., Hellawell, C. J., & Braddock, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.175 · Cited by 105
Coexistence of gastrointestinal stromal tumors with other neoplasms
Liszka, Ł., Zielińska‐Pająk, E., Pająk, J., Gołka, D., & Huszno, J. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2082-4 · Cited by 114
KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations
Simon, R., Panussis, S., Maurer, R. E., Spichtin, H., Glatz, K., Tapia, C., Mirlacher, M., Rufle, A., Torhorst, J. K. H., & Sauter, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0597-3 · Cited by 102
Promise and pitfalls of quantitative imaging in oncology clinical trials
Kurland, B. F., Gerstner, E. R., Mountz, J. M., Schwartz, L. H., Ryan, C. W., Graham, M. M., Buatti, J. M., Fennessy, F. M., Eikman, E. A., Kumar, V., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.009 · Cited by 104
Critical care management of cancer patients: cause for optimism and need for objectivity
Darmon, M., & Azoulay, É. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832b68b6 · Cited by 106
Takahashi, T., Nakajima, K., Nishitani, A., Souma, Y., Hirota, S., Sawa, Y., & Nishida, T. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0705-7 · Cited by 107
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Winger, J. A., Hantschel, O., Superti-Furga, G., & Kuriyan, J. (2009) · BMC Structural Biology · doi:10.1186/1472-6807-9-7 · Cited by 101
Ikezoe, T., Nishioka, C., Tasaka, T., Yang, Y., Komatsu, N., Togitani, K., Koeffler, H. P., & Taguchi, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0071 · Cited by 107
The Multiple Endocrine Neoplasia Syndromes
Lakhani, V. T., You, Y. N., & Wells, S. A. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.100305.115303 · Cited by 101
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 117
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma
Frank‐Raue, K., Fabel, M., Delorme, S., Haberkorn, U., & Raue, F. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0695 · Cited by 100
Verweij, J., Casali, P. G., Kotasek, D., Cesne, A. L., Reichard, P., Judson, I. R., Issels, R. D., van Oosterom, A. T., Glabbeke, M. M. V., & Blay, J. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.018 · Cited by 100
Choi, H. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0055-4 · Cited by 100
Imatinib alone and in combination for chronic myeloid leukemia
Druker, B. J. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70042-0 · Cited by 110
Self-citationKitamura, Y., Hirota, S., & Nishida, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01439.x · Cited by 100
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 114
Interstitial Cells in the Musculature of the Gastrointestinal Tract: Cajal and Beyond
Rumessen, J. J., & Vanderwinden, J. (2003) · International review of cytology · doi:10.1016/s0074-7696(03)29004-5 · Cited by 100
Mali, R. S., Ramdas, B., Ma, P., Shi, J., Munugalavadla, V., Sims, E., Wei, L., Vemula, S., Nabinger, S. C., Goodwin, C. B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.016 · Cited by 99
Sakurai, S., Hasegawa, T., Sakuma, Y., Takazawa, Y., Motegi, A., Nakajima, T., Saito, K., Fukayama, M., & Shimoda, T. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.008 · Cited by 99
Qubaiah, O., Devesa, S. S., Platz, C. E., Huycke, M. M., & Dores, G. M. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0328 · Cited by 99
Glabbeke, M. M. V., Verweij, J., Casali, P. G., Simes, J. R., Cesne, A. L., Reichardt, P., Issels, R. D., Judson, I. R., van Oosterom, A. T., & Blay, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.029 · Cited by 106
Robson, M. E., Glogowski, E., Sommer, G., Antonescu, C. R., Nafa, K., Maki, R. G., Ellis, N. A., Besmer, P., Brennan, M. F., & Offit, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0110 · Cited by 99
Protein kinases and phosphatases as therapeutic targets in cancer
Ventura, J., & Nebreda, Á. R. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0005-0 · Cited by 111
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Zhang, C., Ibrahim, P. N., Zhang, J., Burton, E. A., Habets, G., Zhang, Y., Powell, B., West, B. L., Matusow, B., Tsang, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219457110 · Cited by 95
Pulmonary toxicities from targeted therapies: a review
Barber, N. A., & Ganti, A. K. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0199-0 · Cited by 101
“Pediatric-type” Gastrointestinal Stromal Tumors in Adults
Rege, T. A., Wagner, A. J., Corless, C. L., Heinrich, M. C., & Hornick, J. L. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31820e5f7d · Cited by 97
Self-citationGastrointestinal stromal tumors (GISTs): point mutations matter in management, a review
Oppelt, P. J., Hirbe, A. C., & Tine, B. A. V. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.15 · Cited by 102
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Heymach, J. V., Desai, J., Manola, J. B., Davis, D. W., McConkey, D. J., Harmon, D. C., Ryan, D. P., Goss, G., Quigley, T., den Abbeele, A. D. V., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0157 · Cited by 97
Self-citationInhibitory effect of imatinib on normal progenitor cells in vitro
Bartolović, K., Balabanov, S., Hartmann, U., Komor, M., Boehmler, A. M., Bühring, H., Möhle, R., Hoelzer, D. F., Kanz, L., Hofmann, W., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1535 · Cited by 97
Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Kontos, C. K., Christodoulou, M., & Scorilas, A. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990091 · Cited by 103
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Antolín, A. A., Workman, P., Mestres, J., & Al‐Lazikani, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923115828 · Cited by 111
The history of myeloproliferative disorders: before and after Dameshek
Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404946 · Cited by 127
Bonvalot, S., Cavalcanti, A., Pechoux, C. L., Terrier, P., Vanel, D., Blay, J., Cesne, A. L., & Elias, D. M. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.04.010 · Cited by 96
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
Hägerstrand, D., Hesselager, G., Achterberg, S., Bolin, U. W., Kowanetz, M., Kastemar, M., Heldin, C., Isaksson, A., Nistér, M., & Östman, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209497 · Cited by 100
Kamiyama, Y., Aihara, R., Nakabayashi, T., Mochiki, E., Asao, T., Kuwano, H., Oriuchi, N., & Endo, K. (2005) · World Journal of Surgery · doi:10.1007/s00268-005-0045-6 · Cited by 96
Pauwels, P., Dêbiec‐Rychter, M., Stul, M. S., Wever, I. D., van Oosterom, A. T., & Sciot, R. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02179.x · Cited by 96
Jung, E.-J., Jung, E., Min, S. Y., Kim, M. A., & Kim, W. H. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.002 · Cited by 102
Advances in the treatment of gastrointestinal stromal tumours
Judson, I. R., & Demetri, G. D. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm410 · Cited by 99
Self-citationPfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics
Suehara, Y., Kondo, T., Seki, K., Shibata, T., Fujii, K., Gotoh, M., Hasegawa, T., Shimada, Y., Sasako, M., Shimoda, T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1478 · Cited by 95
Lewis, N. L., Lewis, L. D., Eder, J. P., Reddy, N. J., Guo, F., Pierce, K. J., Olszanski, A. J., & Cohen, R. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8487 · Cited by 96
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
Sobrero, A., & Bruzzi, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4162 · Cited by 100
Janku, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3373 · Cited by 94
Gastrointestinal Stromal Tumors: The GIST of Precision Medicine
Mei, L., Smith, S. C., Faber, A. C., Trent, J. C., Grossman, S. R., Stratakis, C. A., & Boikos, S. A. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.006 · Cited by 101
Cavnar, M. J., Seier, K., Curtin, C. E., Balachandran, V. P., Coit, D. G., Yoon, S. S., Crago, A. M., Strong, V. E. M., Tap, W. D., Gönen, M., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003277 · Cited by 101
Self-citationFierro, F. A., Illmer, T., Jing, D., Schleyer, E., Ehninger, G., Boxberger, S., & Bornhäuser, M. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00438.x · Cited by 100
del Muro, X. G., Pousa, A. L., Martín‐Broto, J., Buesa, J., Martínez‐Trufero, J., Casado, A., Poveda, A. M., Cruz, J., Bover, I., & Maurel, J. (2005) · Cancer · doi:10.1002/cncr.21384 · Cited by 94
C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas
Huo, L., Sugimura, J., Tretiakova, M., Patton, K. T., Gupta, R., Popov, B. V., Laskin, W. B., Yeldandi, A. V., Teh, B. T., & Yang, X. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.01.011 · Cited by 94
Wakai, T., Kanda, T., Hirota, S., Ohashi, A., Shirai, Y., & Hatakeyama, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601819 · Cited by 94
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.